Elevated plasma ghrelin level in underweight patients with chronic obstructive pulmonary disease.

Ghrelin, a novel growth hormone-releasing peptide, has been shown to cause a positive energy balance by reducing fat use and stimulating food intake. This study investigated whether plasma ghrelin is associated with clinical parameters in patients with chronic obstructive pulmonary disease. Plasma ghrelin was measured in 50 patients and 13 control subjects, together with anabolic and catabolic factors. Patients were divided into two groups based on body mass index: underweight patients (n = 26) or normal weight patients (n = 24). Plasma ghrelin was significantly higher in underweight patients than in normal weight patients and healthy control subjects. Circulating tumor necrosis factor-alpha, interleukin-6, and norepinephrine were significantly higher in underweight patients than in normal weight patients. Plasma ghrelin correlated negatively with body mass index and correlated positively with catabolic factors such as tumor necrosis factor-alpha and norepinephrine. In addition, plasma ghrelin correlated positively with percent predicted residual volume and residual volume-to-total lung capacity ratio. In conclusion, plasma ghrelin was elevated in underweight patients with chronic obstructive pulmonary disease, and the level was associated with a cachectic state and abnormality of pulmonary function.

[1]  F. Maltais,et al.  Catabolic/anabolic balance and muscle wasting in patients with COPD. , 2003, Chest.

[2]  H. Satoh,et al.  Plasma orexin-A levels and body composition in COPD. , 2003, Chest.

[3]  N. Kohno,et al.  Increased plasma ghrelin level in lung cancer cachexia. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[4]  Márta Korbonits,et al.  The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. , 2002, The Journal of clinical endocrinology and metabolism.

[5]  W. Shimizu,et al.  Elevated Circulating Level of Ghrelin in Cachexia Associated With Chronic Heart Failure: Relationships Between Ghrelin and Anabolic/Catabolic Factors , 2001, Circulation.

[6]  A. Ionescu,et al.  Inflammatory response and body composition in chronic obstructive pulmonary disease. , 2001, American journal of respiratory and critical care medicine.

[7]  M. Yamaki,et al.  A novel pathophysiologic phenomenon in cachexic patients with chronic obstructive pulmonary disease: the relationship between the circadian rhythm of circulating leptin and the very low-frequency component of heart rate variability. , 2001, American journal of respiratory and critical care medicine.

[8]  K. Hosoda,et al.  Ghrelin, an endogenous growth hormone secretagogue, is a novel orexigenic peptide that antagonizes leptin action through the activation of hypothalamic neuropeptide Y/Y1 receptor pathway. , 2001, Diabetes.

[9]  M. Nakazato,et al.  A role for ghrelin in the central regulation of feeding , 2001, Nature.

[10]  K. Kangawa,et al.  Ghrelin and des-acyl ghrelin: two major forms of rat ghrelin peptide in gastrointestinal tissue. , 2000, Biochemical and biophysical research communications.

[11]  S. Bloom,et al.  The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion. , 2000, Endocrinology.

[12]  M. Tschöp,et al.  Ghrelin induces adiposity in rodents , 2000, Nature.

[13]  M. Nakazato,et al.  Ghrelin is a growth-hormone-releasing acylated peptide from stomach , 1999, Nature.

[14]  J. Vestbo,et al.  Prognostic value of nutritional status in chronic obstructive pulmonary disease. , 1999, American journal of respiratory and critical care medicine.

[15]  C. Lang,et al.  Increased protein synthesis after acute IGF-I or insulin infusion is localized to muscle in mice. , 1998, American journal of physiology. Endocrinology and metabolism.

[16]  C. Pichard,et al.  Administration of growth hormone to underweight patients with chronic obstructive pulmonary disease. A prospective, randomized, controlled study. , 1997, American journal of respiratory and critical care medicine.

[17]  P. Macklem,et al.  Nutritional status and mortality in chronic obstructive pulmonary disease. , 1996, American journal of respiratory and critical care medicine.

[18]  C. Carella,et al.  Body composition, bone metabolism, and heart structure and function in growth hormone (GH)-deficient adults before and after GH replacement therapy at low doses. , 1993, The Journal of clinical endocrinology and metabolism.

[19]  N. Anthonisen,et al.  Body weight in chronic obstructive pulmonary disease. The National Institutes of Health Intermittent Positive-Pressure Breathing Trial. , 1989, The American review of respiratory disease.

[20]  E BERGLUND,et al.  Spirometric studies in normal subjects. I. Forced expirograms in subjects between 7 and 70 years of age. , 2009, Acta medica Scandinavica.